Other way around. Companies do not get rewarded for lack of efficiency and expediency. The longer we wait...the more dilution, OS and Float. That is why the pps has been cut in half. The market tells the tangible story...not hoping and wishing. Also, the longer we wait, shows lack of demand for the technology...i.e. 30 patient enrollment. Quick enrollment demonstrates word getting around via efficacy...i.e. first come first serve demand! Keep in mind, several patients have been treated for several, actually, many many months...This is not a double blind placebo controlled trial...this is an open labeled objective VL load assessment.
Market Data 
Markets 
AI
